Abstract
Background:
The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD.
Objective:
To examine the use of statins in CKD.
Methods:
A review of relevant literature.
Results/conclusion:
Current evidence from clinical trials in CKD patients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
MeSH terms
-
Atherosclerosis / complications
-
Atherosclerosis / drug therapy
-
Atherosclerosis / prevention & control
-
Cardiac Surgical Procedures
-
Cardiovascular Diseases / etiology
-
Cardiovascular Diseases / mortality
-
Cardiovascular Diseases / prevention & control
-
Cholesterol / blood
-
Cholesterol / physiology
-
Chronic Disease
-
Clinical Trials as Topic
-
Diabetic Nephropathies / enzymology
-
Diabetic Nephropathies / etiology
-
Diabetic Nephropathies / pathology
-
Diabetic Nephropathies / prevention & control
-
Endothelium, Vascular / metabolism
-
Endothelium, Vascular / pathology
-
Extracellular Matrix Proteins / metabolism
-
Fibrosis
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Inflammation / complications
-
Inflammation / metabolism
-
Inflammation / pathology
-
Kidney Failure, Chronic / blood
-
Kidney Failure, Chronic / complications
-
Kidney Failure, Chronic / drug therapy*
-
Kidney Failure, Chronic / therapy
-
Lipids / blood
-
Matrix Metalloproteinases / metabolism
-
Multicenter Studies as Topic
-
Postoperative Complications / prevention & control
-
Renal Dialysis*
Substances
-
Extracellular Matrix Proteins
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Lipids
-
Cholesterol
-
Matrix Metalloproteinases